FOGSI Guidelines on Hypertensive Disorders of Pregnancy
I notice the evidence provided does not contain specific FOGSI (Federation of Obstetric and Gynaecological Societies of India) guidelines, but rather includes ISSHP (International Society for the Study of Hypertension in Pregnancy) 2018 guidelines and other international recommendations that inform global practice, including in India.
Key Management Principles Based on Current International Guidelines
Blood Pressure Thresholds and Treatment
Severe hypertension (≥160/110 mm Hg) requires urgent treatment in a monitored setting using oral nifedipine, IV labetalol, or IV hydralazine as first-line agents 1. This is non-negotiable regardless of the specific hypertensive disorder.
For non-severe hypertension:
- Treat BP consistently ≥140/90 mm Hg in clinic (or ≥135/85 mm Hg at home) 1
- Target diastolic BP of 85 mm Hg (systolic 110-140 mm Hg) 1
- Stop or reduce medications if diastolic BP falls <80 mm Hg 1
First-line maintenance agents: methyldopa, labetalol, oxprenolol, nifedipine 1 Second/third-line agents: hydralazine, prazosin 1
This represents a shift toward tighter BP control compared to older guidelines, based on evidence from the CHIPS trial showing reduced maternal complications without fetal harm 1.
Preeclampsia Diagnosis and Monitoring
Preeclampsia is defined as gestational hypertension (after 20 weeks) PLUS one or more of:
- Proteinuria (≥30 mg/mmol protein/creatinine ratio) 1
- Maternal organ dysfunction (renal, liver, neurological, hematological)
- Uteroplacental dysfunction 1
Critical point: Proteinuria is no longer required for diagnosis if other organ dysfunction is present 1.
All women with preeclampsia must be assessed in hospital at first diagnosis 1. Stable patients may transition to outpatient management only after confirming stability and reliable patient monitoring.
Magnesium Sulfate for Seizure Prophylaxis
Administer MgSO₄ to women with preeclampsia who have:
- Proteinuria AND severe hypertension, OR
- Hypertension with neurological signs/symptoms 1
In low-resource settings, all women with preeclampsia should receive MgSO₄: 4g IV or 10g IM loading dose, followed by 5g IM every 4 hours or 1g/hour infusion until delivery and ≥24 hours postpartum 1.
Maternal Monitoring Protocol
Minimum twice-weekly laboratory testing including 1:
- Complete blood count (hemoglobin, platelets)
- Liver enzymes (AST, ALT, LDH)
- Renal function (creatinine, electrolytes, uric acid)
- Proteinuria assessment if not already present
Elevated uric acid correlates with worse maternal and fetal outcomes and should prompt detailed fetal growth assessment, though it should not solely determine delivery timing 1.
Fetal Surveillance
Initial assessment at diagnosis to confirm fetal well-being, then:
- Every 2 weeks if initial assessment normal 1
- More frequent monitoring (amniotic fluid, umbilical artery Doppler) with fetal growth restriction 1
Delivery Timing
Deliver at 37 weeks + 0 days gestation for preeclampsia without complications 1.
Deliver earlier if any of the following develop 1:
- Severe hypertension refractory to 3 antihypertensive classes
- Progressive thrombocytopenia
- Progressively abnormal liver or renal function tests
- Pulmonary edema
- Severe neurological features (intractable headache, visual scotomata, seizures)
- Non-reassuring fetal status
For gestational hypertension without preeclampsia features, optimal delivery timing is 38-39 weeks, though this requires confirmation in randomized trials 1.
Prevention Strategies
Aspirin 150 mg daily should be initiated before 16 weeks gestation for women at high risk, identified through combined first-trimester screening (maternal risk factors, BP, placental growth factor, uterine artery Doppler) 1. This prevents preterm preeclampsia specifically, not term preeclampsia.
Chronic Hypertension Management
Baseline testing at first diagnosis 1:
- Complete blood count
- Liver enzymes and function tests
- Serum creatinine, electrolytes, uric acid
- Urinalysis with protein/creatinine ratio
- Renal ultrasound if creatinine or urinalysis abnormal
This establishes baseline for detecting superimposed preeclampsia, which complicates up to 25% of chronic hypertension pregnancies 1.
Home BP monitoring is mandatory for white-coat hypertension diagnosis and useful for chronic hypertension management 1. Verify device accuracy against calibrated equipment before use, as ~25% of automated devices are inaccurate in pregnancy 1.
Common Pitfalls to Avoid
- Do not wait for proteinuria to diagnose preeclampsia—it's present in only ~75% of cases 1
- Do not use plasma volume expansion routinely in preeclampsia 1
- Do not rely on hyperreflexia for diagnosis—it's nonspecific and observer-dependent 1
- Do not ignore gestational hypertension—25% progress to preeclampsia 1
- Do not use uric acid alone to time delivery, despite its prognostic value 1
Postpartum Considerations
Women with HDP require long-term cardiovascular risk assessment and lifestyle modification counseling, as they face increased lifetime risk of hypertension, stroke, and cardiovascular disease 2. This represents an emerging area of guideline focus that is inadequately addressed in many healthcare systems 3.
Note on FOGSI-Specific Guidelines: While FOGSI likely has published guidelines on HDP, they were not included in the evidence provided. Indian practitioners should consult FOGSI's official publications directly, though the ISSHP 2018 guidelines 1 represent the international consensus that typically informs regional adaptations, including in India.